Synthesis and antimycobacterial activities of non-purine analogs of 6-aryl-9-benzylpurines: Imidazopyridines, pyrrolopyridines, benzimidazoles, and indoles

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 11, 2011, Pages 3483-3491

  Khoje, Abhijit Datta ^a   Charnock, Colin ^b   Wan, Baojie ^c   Franzblau, Scott ^c   Gundersen, Lise Lotte ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO METROPOLITAN UNIVERSITY   (Norway)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Deazapurines; Heterocycles; Tuberculosis

Indexed keywords

2,6 DICHLORO N (4 METHOXYBENZYL) 3 NITROPYRIDIN 4 AMINE; 3 BROMO N1 (4 METHOXYBENZYL)BENZENE 1,2 DIAMINE; 3 DEAZAPURINE; 3,7 DEAZAPURINE; 4 (FURAN 2 YL) 1 (4 METHOXYBENZYL) 1H PYRROLO[2,3 B]PYRIDINE; 4 (FURAN 2 YL) 1 (4 METHOXYBENZYL) 1H PYRROLO[3,2 C]PYRIDINE; 4 (FURAN 2 YL) 3 (4 METHOXYBENZYL) 3H IMIDAZO[4,5 C]PYRIDINE; 4 (FURAN 2 YL) N (4 METHOXYBENZYL) 3 NITROPYRIDIN 2 AMINE; 4 (FURAN 2 YL) N2 (4 METHOXYBENZYL) 3 NITROPYRIDINE 2,3 DIAMINE; 4 BROMO 1 (4 METHOXYBENZYL) 1H BENZO[D]IMIDAZOLE; 4 BROMO 6 CHLORO 1 (4 METHOXYBENZYL) 1H PYRROLO[2,3 B]PYRIDINE; 4 CHLORO 1 (4 METHOXYBENZYL) 1H PYRROLO[2,3 B]PYRIDINE; 4 CHLORO 4 (FURAN 2 YL) N (4 METHOXYBENZYL) 3 NITROPYRIDIN 2 AMINE; 4 CHLORO 4 (FURAN 2 YL) N2 (4 METHOXYBENZYL)PYRIDINE 2,3 DIAMINE; 4,6 DICHLORO 1 (4 METHOXYBENZYL) 1H PYRROLO[3,2 C]PYRIDINE; 5 CHLORO 7 (FURAN 2 YL) 3 (4 METHOXYBENZYL) 3H IMIDAZO[4,5 B]PYRIDINE; 6 CHLORO 1 (4 METHOXYBENZYL) 1H PYRROLO[3,2 C]PYRIDINE; 6 CHLORO 2 (FURAN 2 YL) N (4 METHOXYBENZYL) 3 NITROPYRIDINE 4 DIAMINE; 6 CHLORO 2 (FURAN 2 YL) N4 (4 METHOXYBENZYL) 3 NITROPYRIDINE 3,4 DIAMINE; 6 CHLORO 4 (FURAN 2 YL) 1 (4 METHOXYBENZYL) 1H IMIDAZO[4,5 C]PYRIDINE; 6 CHLORO 4 (FURAN 2 YL) 1 (4 METHOXYBENZYL) 1H PYRROLO[2,3 B]PYRIDINE; 6 CHLORO 4 (FURAN 2 YL) 1 (4 METHOXYBENZYL) 1H PYRROLO[3,2 C]PYRIDINE; 7 (FURAN 2 YL) 3 (4 METHOXYBENZYL) 3H IMIDAZO[4,5 B]PYRIDINE; 7 DEAZAPURINE; ANTIINFECTIVE AGENT; BENZIMIDAZOLE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; INDOLE DERIVATIVE; PYRROLOPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTITUBERCULAR AGENTS; BENZIMIDAZOLES; CERCOPITHECUS AETHIOPS; IMIDAZOLES; INDOLES; MYCOBACTERIUM TUBERCULOSIS; PURINES; PYRIDINES; VERO CELLS;

MAMMALIA; MYCOBACTERIUM TUBERCULOSIS;

EID: 79957498236     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.04.023     Document Type: Article

References (29)

1. See for instance: Global Alliance for TB Drug Development, The need for new TB drugs (2005; www.tballiance.org ).
2. V. Bhowruth, L.G. Dover, and G.S. Besra Prog. Med. Chem. 45 2007 169
3. A.K. Bakkestuen, L.-L. Gundersen, G. Langli, F. Liu, and J.M.J. Nolsøe Bioorg. Med. Chem. Lett. 10 2000 1207
4. L.-L. Gundersen, J. Nissen-Meyer, and B. Spilsberg J. Med. Chem. 45 2002 1383
5. G. Andresen, L.-L. Gundersen, J. Nissen-Meyer, F. Rise, and B. Spilsberg Bioorg. Med. Chem. Lett. 12 2002 567
6. A.K. Bakkestuen, L.-L. Gundersen, and B.T. Utenova J. Med. Chem. 48 2005 2710
7. M. Brændvang, and L.-L. Gundersen Bioorg. Med. Chem. 13 2005 6360
8. M. Brændvang, and L.-L. Gundersen Bioorg. Med. Chem. 15 2007 7144
9. M. Brændvang, V. Bakken, and L.-L. Gundersen Bioorg. Med. Chem. 17 2009 6512
10. M. Brændvang, and L.-L. Gundersen Tetrahedron Lett. 48 2007 3057
11. M. Brændvang, C. Charnock, and L.-L. Gundersen Bioorg. Med. Chem. Lett. 19 2009 3297
12. P.O. Miranda, and L.-L. Gundersen Arch. Pharm. Chem. Life Sci. 343 2010 40
13. M.L. Read, M. Brændvang, P.O. Miranda, and L.-L. Gundersen Bioorg. Med. Chem. 18 2010 3885
14. A.D. Khoje, A. Kulendrn, C. Charnock, B. Wan, S.G. Franzblau, and L.-L. Gundersen Bioorg. Med. Chem. 18 2010 7274
15. A.D. Khoje, and L.-L. Gundersen Tetrahedron Lett. 52 2011 523
16. C. Crey-Desbiolles, and M. Kotera Bioorg. Med. Chem. 14 2006 1935
17. A.M. Palmer, G. Münch, C. Brehm, P.J. Zimmermann, W. Buhr, M.P. Feth, and W.A. Simon Bioorg. Med. Chem. 16 2008 1511
18. Dhanak, D.; Newlander, K. A. U.S. Pat. Appl. 2007149561, 2007, 108.
19. T. Chen, X.-G. Xu-Guang Liu, and M. Shi Tetrahedron 63 2007 4874
20. M. Frohn, V. Viswanadhan, A.J. Pickrell, J.E. Golden, K.M. Muller, W. Roland, R.W. Bürli, G. Biddlecome, S.C. Yoder, N. Rogers, J.H. Dao, R. Hungate, and J.R. Allen Bioorg. Med. Chem. Lett. 18 2008 5023
21. See for instance: D.R. Goldberg, T. Butz, M.G. Cardozo, R.J. Eckner, A. Hammach, J. Huang, S. Jakes, S. Kapadia, K. Kashem, S. Lukas, T.M. Morwick, M. Panzenbeck, U. Patel, S. Pav, G.W. Peet, J.D. Peterson, A.S. Prokopowicz III, R.J. Snow, R. Sellati, H. Takahashi, J. Tan, M.A. Tschantz, X.-J. Wang, Y. Wang, J. Wolak, P. Pla Xiong, and N. Mos J. Med. Chem. 46 2003 1337
22. V.I. Ognyanov, C. Balan, A.W. Bannon, Y. Bo, C. Dominguez, C. Fotsch, V.K. Gore, L. Klionsky, V.V. Ma, Y.-X. Qian, R. Tamir, X. Wang, N. Xi, S. Xu, D. Zhu, N.R. Gavva, J.J.S. Treanor, and M.H. Norman J. Med. Chem. 49 2006 3719
23. See for instance: V. Kozmik, B. Kosata, J. Svoboda, and M. Kuchar Collect. Czech. Chem. Commun. 71 2006 679
24. G. Vavilina, A. Zicmanis, S. Drozdova, P. Mekss, and M. Klavins Chem. Heterocycl. Compd. 44 2008 530
25. L.A. Collins, and S.G. Franzblau Antimicrob. Agents Chemother. 41 1997 1004
26. K. Falzari, Z. Zhu, D. Pan, H. Liu, P. Hongmanee, and S.G. Franzblau Antimicrob. Agents Chemother. 49 2005 1447
27. S.H. Cho, S. Warit, B. Wan, C.H. Hwang, G.F. Pauli, and S.G. Franzblau Antimicrob. Agents Chemother. 51 2007 1380
28. Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. CLSI document M100-S20, Wayne, PA, USA 2010.
29. Clinical and Laboratory Standards Institute (CLSI): Method for dilution antimicrobial susceptibility tests for bacterial that grow aerobically; approved standard - 8th ed. CLSI document M07-A8, Wayne, PA, USA 2009.